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ABSTRACT  
Polymer-directed enzyme prodrug therapy (PDEPT) and polymer enzyme liposome therapy 
(PELT) are two-step therapies developed to provide anticancer drugs site-selective intratumoral 
accumulation and release. Nanomedicines, such as polymer-drug conjugates and liposomal 
drugs, accumulate in the tumor site due to extravasation-dependent mechanism (enhanced 
permeability and retention – EPR – effect), and further need to cross the cellular membrane 
and release their payload in the intracellular compartment. The subsequent administration of a 
polymer-enzyme conjugate able to accumulate in the tumor tissue and to trigger the 
extracellular release of the active drug showed promising preclinical results. The development 
of polymer-enzyme, polymer-drug conjugates and liposomal drugs had undergone a vast 
advancement over the past decades. Several examples of enzyme mimics for in vivo therapy 
can be found in the literature. Moreover, polymer therapeutics often present an enzyme-
sensitive mechanism of drug release. These nanomedicines can thus be optimal substrates for 
PDEPT and this review aims to provide new insights and stimuli towards the future perspectives 
of this promising combination.  
GRAPHICAL ABSTRACT 
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1. INTRODUCTION 
The concept of using a specific trigger to convert a prodrug into an active moiety has been 
developed since the late ϴϬ’s, ǁith the ǁoƌk of Bagshawe and colleagues on antibody-directed 
enzyme prodrug therapy (ADEPT) [1] and Huber and colleagues on viral/gene-directed enzyme 
prodrug therapy (VGEDT) [2].   
More than a decade after, Duncan and Satchi introduced a new stimuli-dependent prodrug 
activation mechanism, known as polymer-directed enzyme prodrug therapy (PDEPT) [3] (Fig. 1), 
in which the trigger is a polymer-enzyme conjugate that promotes the release of an active drug 
from a polymeric backbone. The same idea was later applied also to liposomal formulations, 
developing the so-called polymer enzyme liposome therapy (PELT) (Fig. 1) [4]. PDEPT combined 
the knowledge on polymer-enzyme conjugation (to improve stability and reduce immune 
responses upon administration of proteins) and polymer-drug conjugation for tumor-targeted 
drug therapy. The development of polymer therapeutics in the early ϮϬϬϬ’s, ǁith the fiƌst 
polymeric prodrugs (PK1) reaching clinical trials [5], highlighted the need for a targeted therapy 
to trigger the release of the active compound in a particular site of action. Relying solely on the 
enhanced permeability and retention (EPR) effect [6] for tumor accumulation is not sufficient to 
guarantee intracellular accumulation of an active drug. Tumor heterogeneity due to individual 
differences in tumor size, vasculature and stroma, as well as immune system components 
infiltration [7] can dramatically alter the biodistribution and accumulation of macromolecular 
drugs. For this reason, over the past decades, tumor-specific targeting agents were investigated 
to modulate the biodistribution and clearance of different classes of nanomedicines [8]. The 
receptor/ligand-mediated targeting can also affect the internalization pathway, promoting 
intracellular accumulation of the active moiety and carrier payload. Alternative approaches 
have been developed to improve cancer tissue targeting by exploiting specific physical and 
pathological conditions of the tumor microenvironment to trigger the release of the drug [4, 9, 
10]. PDEPT and PELT can be considered further in this direction, not only by exploiting the 
conditions naturally present at the tumor site, but also by triggering the desired response via 
co-administration of the enzyme required to promote drug release.  
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In this review, we will describe the fundamental aspects for the rational design of PDEPT and 
PELT systems, with particular focus on future perspectives in this field, which potential has not 
yet been fully explored. 
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Figure 1. Polymer-directed enzyme prodrug therapy (PDEPT) and polymer enzyme liposome 
therapy (PELT) mechanisms. 
2. PROOF OF CONCEPT 
2.1. Polymer-directed enzyme prodrug therapies (PDEPT): 
The first PDEPT system developed [3] consists of (I) N-(2-hydroxypropyl)methacrylamide 
(HPMA) copolymer-Doxorubicin conjugate [11] as a polymeric prodrug targeting the tumor via 
the EPR effect, and (II) HPMA copolymer-Cathepsin B conjugate as the enzymatic trigger 
system. Doxorubicin was conjugated to the HPMA copolymer via a Gly-Phe-Leu-Gly linker. This 
peptidic sequence was designed to be cleaved intracellularly by lysosomal cysteine proteases, 
such as Cathepsin B overexpressed in several cancers [12]. In order to obtain an anticancer 
activity, the polymeric prodrug needs to reach the tumor site, be internalized into cancer cells 
via pinocytosis, and be released in the lysosome following a specific enzymatic cleavage. To 
increase the intracellular availability of Doxorubicin and change its release kinetics, Satchi-
Fainaro and Duncan thought of adding a different mechanism for intratumoral extracellular 
drug release by exogenously administering an enzyme (Cathepsin B) that will accumulate in the 
cancer tissue via the EPR effect similarly to the way HPMA copolymer-Doxorubicin prodrug 
conjugate does. To guarantee that Cathepsin B reaches the target site in its active form, the 
enzyme was conjugated to a polymeric chain of HPMA copolymer, which should prevent 
immune-recognition and degradation in the bloodstream. After reaching the cancer tissue, the 
HPMA copolymer-Cathepsin B conjugate cleaves the Gly-Phe-Leu-Gly linker and releases the 
active drug. To avoid the release of the free drug in the bloodstream, the polymer-enzyme 
conjugate is injected at a later stage, about 5 hours later, when the polymer-drug conjugate has 
been cleared from the bloodstream according to its pharmacokinetic profile [13]. The 
sequential administration of PK1 and HPMA copolymer-Cathepsin B displayed site-selective 
drug release and superior anticancer activity compared to the polymer-drug conjugate 
administered alone.  
A further evolution of the concept was the development of a PDEPT system involving a non-
mammalian enzyme, in order to avoid interference from physiological enzymes and inhibitors 
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present in the mammalian bloodstream. For this purpose, Satchi-Fainaro and Duncan selected -lactamase as the triggering non-mammalian enzyme that hydrolyzes -lactams to substituted -amino acids [14]. The conjugation of this enzyme to a polymeric chain (HPMA copolymer) 
becomes in this case of crucial importance to allow not only its selective accumulation at the 
tumor site, but also to mask the antigenic determinants, i.e. the immunogenicity, of the non-
mammalian enzyme. The second component of this two-step therapy is a HPMA copolymer-
based prodrug of Doxorubicin, where the active drug is conjugated via a cephalosporin linker, 
which contains a -lactam ring, a specific substrate of the -lactamase. Again, in this case, the 
two-step therapy was not toxic and improved the anticancer efficacy of the HPMA copolymer-
Doxorubicin conjugate [14].  
In the direction of developing a polymer-macromolecule conjugate with enzymatic activity and 
with reduced immunogenicity, a HPMA-catalytic antibody was developed [15]. HPMA 
copolymer was conjugated to aldolase antibody 38C2, which is one of the most efficient 
antibodies that catalyze the aldol cleavage using substrates that are not recognized by human 
enzymes. In addition, the immunogenicity of the antibodies can be easily reduced not only by 
their conjugation to the polymeric chain, but also by selecting humanized antibodies. Thanks to 
these features, the polymer-catalytic antibody conjugate was developed as part of the two-step 
therapy. An Etoposide prodrug was designed to be selectively activated by the catalytic 
antibody 38C2, and showed superior safety compared to the non-modified Etoposide [16]. 
Albeit preliminary, this investigation reported the feasibility of a retro-aldol/retro-Michael 
reaction activation method for the release of an active drug via a catalytic antibody-mediated 
reaction. In order to become suitable for parenteral administration, the Etoposide prodrug 
should be further conjugated to a polymer that will guarantee preferential accumulation at the 
target site. Furthermore, the HPMA copolymer-antibody conjugate should be proven safe for in 
vivo administration. 
2.2. Polymer enzyme liposome therapy (PELT)  
Albeit the PELT concept has been described by Duncan and co-workers already in 2001 [4], the 
proof of concept for its activity has been achieved only recently [17]. Ferguson and Satchi-
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Fainaro described the preparation of two polymer-phospholipase conjugates to promote the 
release of anthracycline from commercially-available liposomal formulations. Ferguson et al. 
conjugated HPMA copolymer to phospholipase C [17] . This enzyme was able to promote the 
degradation of the lipidic membrane of liposomes, increasing the drug release from these 
formulations [18], and maintaining its enzymatic activity following conjugation to the non-
biodegradable HPMA copolymer. Ferguson et al. designed and synthesized a conjugate of 
dextrin-Phospholipase A2 (PLA2) [17, 19], an enzyme with proven anticancer activity by targeting 
the deregulated lipid metabolism in cancer [20]. The general toxicity of the PLA2 toxin following 
in vivo administration is, nevertheless, the limiting factor for its use as a therapeutic drug. 
Consequently, conjugation to a polymer is crucial for reducing the non-specific toxicity of the 
enzyme. Dextrin has the advantage of being biodegradable and able to confer stability to the 
enzyme during circulation in the bloodstream, while allowing for unmasking of the protein at 
the taƌget site, aĐĐoƌdiŶg to the PolǇŵeƌ Masked−UŶŵasked PƌoteiŶ TheƌapǇ ;PUMPTͿ model, 
following treatment with -amylase [21]. The two polymer-enzyme conjugates described above 
retained the catalytic activity of the native enzyme, and were able to promote drug release 
from non-polyethylene glycol (PEG) modified (non-PEGylated) (DaunoXome®) and, to a lesser 
extent, also from PEGylated liposomes (Caelyx®), probably due to PEG steric hindrance. 
Furthermore, when dextrin-PLA2 was exposed to -amylase the rate of anthracycline release 
from non-PEGylated liposomes increased. 
Although intriguing concepts, only a small number of papers were published on PELT and PDEPT 
(Table I), and in all of those reported studies, the in vivo results were preliminary or missing.  
Despite the poor appeal of the two-step therapies from the research side, the field of polymer 
conjugation expanded dramatically over the last 20 years, leading to the development of 
numerous polymer-enzyme conjugates, polymer-drug conjugates and liposomal systems. 
Several of these nanomedicines can in principle constitute one of the components of these 
two-step therapies.  
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Table I: PDEPT and PELT systems developed  
CONJUGATE 
NAME 
POLYMER ENZYME DRUG FORMULATION ENZYME TYPE STATUS REF 
PDEPT I HPMA 
copolymer 
Cathepsin B HPMA-Doxorubicin Endogenous POC – In vivo 
Preclinical 
development 
[3] 
PDEPT II HPMA 
copolymer 
-lactamase HPMA-Doxorubicin Exogenous  POC  – In vivo 
Preclinical 
development 
[14] 
PDEPT III 
HPMA 
copolymer 
catalytic 
antibody 38C2 
Etoposide prodrug Exogenous  POC – In vitro 
Preclinical 
development 
[15] 
PELT HPMA 
copolymer 
Phospholipase C PEGylated liposomal 
Doxorubicin (Doxil®) 
Liposomal Adriamycin 
(DaunoXome®) 
Endogenous POC – In vitro 
Preclinical 
development 
[17] 
PELT Dextrin Phopholipase A2 PEGylated liposomal 
Doxorubicin (Doxil®) 
Liposomal Adriamycin 
(DaunoXome®) 
Endogenous POC – In vitro 
Preclinical 
development 
[17] 
PELT+ 
PUMPT 
Dextrin Phopholipase A2 
 
+  amylase 
PEGylated liposomal 
Doxorubicin (Doxil®) 
Liposomal Adriamycin 
(DaunoXome®) 
Endogenous POC – In vitro 
Preclinical 
development 
[17] 
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3. POLYMER-ENZYME CONJUGATES 
At the moment, there are 20 therapies based on recombinant enzymes approved mainly for the 
treatment of rare diseases [22]. The problems in enzyme administration, such as 
immunogenicity, difficulty in targeting and unsatisfactory pharmacokinetics [23], have led to 
the development of delivery systems to enable their in vivo biological therapeutic activity.  So 
far, several polymer-enzyme conjugates have been designed and synthesized (Table II), and 
those have been extensively reviewed before [24-26]. In addition, the use of biodegradable 
polymers can be helpful in masking the immunogenic domain during circulation in the 
bloodstream, while releasing the active enzyme at the site of action, according to the PUMPT 
mechanism [21].   
Over the last few years, conjugation techniques have improved, allowing for site-specific 
conjugation of cleavable linkers between either linear or branched polymer and the enzyme 
[24, 27, 28]. Preserving the activity of the catalytic site is a crucial step in the development of 
polymer-enzyme conjugates, and often a non-specific conjugation of polymers to multiple sites 
dramatically reduces the enzyme activity [29]. Usually the N-terminal amino acid is not involved 
in the binding or activity of the enzyme, and therefore it is an attractive binding site for 
polymers. Furthermore, due to its specific pKa, which differs from the pKa of the side chains of 
Lys, it is suitable for site selective conjugation [30]. Cys are also attractive binding sites, since 
they are rarely present in their reactive form in the enzyme. The reactive thiol group can be 
exposed by selective reduction of the disulfide bond, becoming accessible for conjugation [31]. 
The conjugation to thiol groups can be achieved via non-reversible thioether covalent bonds, 
using maleimide reactive groups, or via redox potential cleavable disulfide bond using polymers 
bearing a thiol group [32]. In addition, besides the traditional chemical conjugation, other 
strategies have been developed, mainly involving enzymes that catalyze the formation of new 
peptidic bonds between one amino acid of the protein and the polymer chain. Among the 
enzymes suitable for conjugation [27], transglutaminase is one of the most common [33, 34], 
but also sortase and other enzymes are used [27, 29]. 
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3.1. Polymer-Enzyme conjugates in clinical use 
Adenosine deaminase. The first polymer-enzyme conjugate to enter the market was the 
PEGylated Adenosine deaminase ADAGEN® (pegademase bovine), for enzyme replacement 
therapy in patients with severe combined immunodeficiency disease (SCID) associated with a 
deficiency of adenosine deaminase (ADA) (Table II) [35]. However, this enzyme is upregulated in 
cancer cells [36, 37], while its overexpression directly correlates to increased tumor malignancy. 
Therefore, its inhibition is desired as anticancer treatment [38]. For this reason, this enzyme 
might not be the best candidate for two-step anticancer therapies.  
Asparaginase. An enzyme with intrinsic anticancer activity might be ideal to fully exploit the 
potential of two-step polymer-derived enzyme prodrug therapy. The cytotoxic properties of 
Asparaginase, a hydrolytic enzyme, are known for more than 50 years [39], and the 
recombinant enzyme is currently available in its native form for the therapy of acute 
lymphoblastic leukemia (ALL) and Non-Hodgkin Lymphoma (NHL) [40]. The enzyme promptly 
reduces the level of Asparagine in serum, cutting the supply to the cancer cells that are not able 
to overcome the amino acid shortage [40]. Since 1994, there is also a PEGylated form on the 
market (Oncaspar®) [41] for the same indications as the native form. As expected, the 
PEGylated Asparaginase decreases the immunogenicity of the recombinant enzyme and can be 
used also in cases of patients who developed hypersensitivity against the native Asparaginase 
[40]. This commercially-available conjugate is based on the recombinant Escherichia coli (E. 
Coli) enzyme that reacts with several 5 kDa PEG succinimidyl succinate chains via the amino 
groups of the enzyme lysine side-chains [42]. Besides Oncaspar®, several other PEG conjugates 
have been developed, differing in shape and molecular weight (MW) of the polymeric chain 
(linear or branched), and following distinct conjugation chemistry (random or site specific) [24, 
31, 43-45]. In addition, several other polymers have been conjugated to Asparaginase, including 
biodegradable polypeptides [46] and polysaccharides [47]. 
Uricase. The third polymer-enzyme conjugate to reach the market was the PEG-Uricase 
polymer therapeutic, known as KRYSTEXXA® [48]. Uricase is a non-mammalian hepatic enzyme 
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not present in humans that catabolizes the oxidation of urate into soluble products (allantoin 
and carbon dioxide) and, for this reason, it is used to treat hyperuricemia [49]. The commercial 
formulation is based on porcine uricase covalently attached to 10 kDa PEG chains via p-
nitrophenol chemistry [50].  Also, in the case of uricase, several PEG conjugates have been 
developed [51, 52], as well as other polymer conjugates [53]. 
3.2. Other polymer-enzyme conjugates  
Trypsin, Chymotrypsin and Papain. Trypsin, chymotrypsin and papain are digestive enzymes 
responsible for protein degradation via peptide bond cleavage. They have also been tested as 
support therapy to reduce the adverse-effects associated with chemotherapy in cancer 
patients, in which they prolonged survival to some extent [54]. They have been extensively 
investigated as substrates for polymer conjugation [24] and dextrin-trypsin conjugates were the 
first proof of concept models for PUMPT [21]. Also in this case, the PEG conjugates were among 
the first to be developed [55-59], but HPMA copolymer conjugates [60-62] and carbohydrate 
derivatives [61, 63, 64] have also been proposed.  
Lysozyme. Lysozyme is an enzyme in the class of the glycosidases and it catalyzes the hydrolysis 
of the beta-(1-4)-glycosidic bond between N-acetylglucosamine sugar (NAG) and N-
acetylmuramic acid sugar (NAM) in peptidoglycan of bacterial and viral cell walls [65]. Lysozyme 
is mainly used for its antibacterial and immunomodulatory activity [66]. However, anticancer 
effects have been reported, probably via direct or indirect activation of the immune system 
[67]. Partially due to its therapeutic effect, but also because it can function as an easily-
available model protein, Lysozyme has been conjugated via several chemistries to a wide range 
of polymers, such as PEG [68, 69], poly (DL-alanine) [70], HPMA copolymers [71], Poly(Glutamic 
acid) (PGA) [72] and Dextran [73]. 
Superoxide dismutase (SOD). Superoxide dismutase serves as the main physiological 
antioxidant system, preventing the effects of reactive oxygen species (ROS). The oxidative 
stress has been correlated with several pathologies, such as hypertension, atherosclerosis, and 
vascular remodeling [74]. In addition, SOD has anti-inflammatory properties [75]. For these 
reasons, SOD has been widely investigated as therapeutic agent for a broad range of diseases 
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(inflammation, cardiovascular, respiratory), but also as a scavenger of radiation damage and to 
prevent carcinogenesis [76]. In order to improve the physicochemical properties of the enzyme, 
SOD was widely conjugated to PEG of different sizes and through different conjugation 
chemistries [23, 77]. SOD has also been conjugated to amphiphilic polymers, such as Pluronic 
block copolymers [78], Poly(2-oxazoline) block copolymers [79], HPMA copolymers [80], 
Dextran [81] and poly(N-vinylpyrrolidone) [82]. 
Ribonuclease. This hydrolytic enzyme catalyzes the degradation of RNA by cleaving the 
phosphodiester bonds [83]. It has intrinsic cytotoxic activity and it reached the clinical trials for 
the treatment of solid tumors, including non-small cell lung, esophageal, and colorectal 
carcinomas [84]. Ribonuclease has been successfully conjugated to HPMA copolymer [85], PEG 
[86] and polysaccharides [87]. 
 
Table II: Polymer-Enzyme conjugates  
POLYMER ENZYME ENZYME TYPE INDICATION REF 
PEG 
Adenosine 
deaminase 
Endogenous 
Adagen® (Pegademase bovine) 
Approved (1990) for SCID  
[35] 
PEG 
Asparaginase Exogenous 
Oncaspar® (Pegaspargase) 
Approved (1994) for ALL.  
[31, 41, 
44, 45] 
Poly(DL-alanine) 
Acute lymphoblastic leukemia 
[46] 
iLevan [47] 
PEG 
Uricase Exogenous 
KRYSTEXXA® (PEG–uricase) 
Approved (2010) for gout and 
hyperuricemia   
[48, 52] 
PVP 
Gout and hyperuricemia   [53] 
PAcM 
HPMA copolymer 
-Chymotrypsin Endogenous Relief from the adverse-effects associated with chemotherapy in 
cancer patients [54] 
[60] 
PEG [55, 56] 
Dextran [63] 
 13 
PEG 
Trypsin Endogenous 
[57] 
HPMA copolymer [61] 
Dextrin [21][61]  
Dextran [64] 
PEG 
Papain Endogenous 
[59] 
HPMA copolymer [62] 
PEG 
Lysozyme Exogenous 
Antibacterial [66] and anticancer 
effect [67] 
[68] 
Poly(DL-alanine) [70] 
PNIPAAm [69] 
PEG 
Superoxide 
dismutase 
Endogenous Anti-inflammatory [75] 
[23, 77] 
Pluronic [78] 
Poly(2-oxazoline) [79] 
HPMA copolymer [80] 
Poly(N-
vinylpyrrolidone) 
[82] 
Dextran [81] 
PEG 
Ribonuclease Endogenous Anticancer activity [84] 
[86]  
HPMA copolymer [85] 
Chitin [87] 
HPMA copolymer Cathepsin B Endogenous  [3] 
Dextrin Phospholipase A2 Endogenous  [19] 
HPMA copolymer Phospholipase C Endogenous   
HPMA copolymer β-lactamase Exogenous  [14] 
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4. ENZYME-SENSITIVE DRUG CONJUGATES 
The polymer-drug conjugate’s or liposome’s sensitivity to the activity of a specific enzyme is a 
fundamental feature of polymer-enzyme directed therapies. The pharmacokinetic profile must 
be known, in order to allow for the second injection of the polymer-enzyme only once the drug-
conjugate reaches the target site, thus avoiding drug leakage into the blood circulation. Many 
of the polymer-drugs developed in the last 20 years rely on enzyme-sensitive drug release 
profile to enhance intratumoral accumulation of the active molecules. Even though, in other 
studies the enzyme-cleavable linker conferred stability or enhanced cellular internalization of 
the supramolecular entity. Nevertheless, several of those nanomedicines have been adequately 
characterized for their in vivo properties to serve as substrates for PELT and PDEPT.  
4.1. Cathepsin-sensitive conjugates 
Cathepsin B-cleavable conjugates. Cathepsin B is a lysosomal cysteine protease that plays a 
major role in proteolysis and is upregulated in several pathologies, including cancer [12].  
Therefore, Cathepsin B-sensitive linkers have been extensively investigated for site-specific 
stimuli triggered drug release. In fact, the first two polymer-conjugates (PK1 and PK2) reaching 
clinical trials were based on the cathepsin-cleavable polypeptide Gly-Phe-Leu-Gly [5, 88]. This 
linker is stable in plasma [89] and guarantees intracellular lysosomal release of the drugs [90]. 
This conjugation strategy allows for the formation of polymer-drug conjugates that are 
significantly more stable in bloodstream than other conjugates, in which the drugs are linked 
via pH-sensitive ester bonds, such as HPMA copolymer-Paclitaxel [91] and HPMA copolymer-
Camptothecin [92] conjugates tested in clinical trials. In addition, PK1 and PK2 pharmacokinetic 
and biodistribution profiles have been evaluated both at preclinical levels in rodents [11] and 
under clinical settings [5, 88], making them ideal candidates for two-step therapies [3].  
Doxorubicin has served as model drug for the development of several Cathepsin B-cleavable 
peptide-based conjugates, such as PEG-based [93], dendrimer-based [94, 95] and several HPMA 
copolymers [96, 97], as well as silica nanoparticles [98] and micelles [99]. However, there were 
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also interesting works focusing on the development of Camptothecin- [100], Gemcitabine- 
[101-103] and Paclitaxel- [102, 104-106] based polymers.  
A particular attention should be noted on the PGA polymer, which is Cathepsin B-sensitive per 
se, without the need for a peptidic enzyme-sensitive linker. The enzymatic degradation of the 
PGA backbone promotes the drug release. Several conjugates have been developed, being the 
most known the Polyglumex, a PGA-Paclitaxel conjugate that reached clinical trials [107], but 
also the PGA-Paclitaxel-E-[c(RGDfK)2] [108], PGA-Doxorubicin-Paclitaxel [109], PGA-
Camptothecin [110],  and PGA-oligonucleotides polyplexes [111-113].  
Indeed, the Gly-Phe-Leu-Gly cathepsin B sensitive linker was used as a strategy to conjugate 
short fragments of other non-biodegradable polymers, such as HPMA copolymers, generating a 
high molecular weight, biodegradable copolymeƌs. KopeĐek’s gƌoup deǀeloped seǀeƌal 
conjugates [114, 115], bearing one drug (paclitaxel  [116], gemcitabine [117], and doxorubicin 
[118]) or two drugs combination (gemcitabine and paclitaxel [119, 120]). 
 All these polymer therapeutics can be substrates for PDEPT therapy in combination with 
polymer-cathepsin B conjugates. 
Other Capthepsin-cleavable conjugates. Besides Cathepsin B, several cathepsins have been 
correlated with primary and metastatic cancers [121]. Among them, Cathepsin K is synthesized 
mainly in osteoclasts, and subsequently secreted to the extracellular matrix where it is involved 
in bone resorption [122]. Thus, it is a perfect target for stimuli-dependent conjugates. So far, a 
small number of polymer bearing Paclitaxel and Alendronate have been developed, using the 
glycine-glycine-proline-norleucine (Gly-Gly-Pro-Nle) peptide, which is cleaved by Cathepsin K 
[123-126].  
4.2. Legumain-sensitive conjugates 
Legumain is an asparaginyl endopeptidase overexpressed in several cancers [127], both in the 
extracellular matrix (ECM) and in the lysosomes. Therefore, linkers presenting asparagine or 
aspartic acid residues, selectively hydrolysable by this enzyme, have been used to develop 
enzyme-sensitive prodrugs. To date, both low MW molecules containing legumain-cleavable 
 16 
linkers [128-130] and polymeric conjugates [131] have been synthesized using peptides 
containing the alanine-alanine-asparagine sequence (Ala-Ala-Asn). Recently, Lin et al. presented 
hyaluronic acid (HA) legumain-sensitive nanogel, based on the same AAN peptide, for the 
delivery of Doxorubicin with a high targeting efficiency, both in vitro and in vivo [132]. 
4.3. Matrix metalloproteinases (MMP)-cleavable conjugates 
MMP are mainly involved in collagen degradation and ECM homeostasis. They are also involved 
in carcinogenesis and metastasis formation by modifying the local ECM that becomes more 
permissive to cancer cells’ migration [133].  As a consequence of their activity on apoptosis, 
angiogenesis and migration, MMP have been investigated as targets for inhibitors with 
anticancer activity, but also as substrates for cleavable polymer-drug conjugates. 
Albeit limited to in vitro characterization, Bruun et al. developed PEGylated lipid-based 
nanoparticles for the delivery of siRNA to the brain that exploited a MMP-sensitive linker to 
trigger the release of the PEG in the cancer site, releasing the active cargo [134]. The concept of 
using a PEGylated shield to protect the formulations in the bloodstream and to exploit a linker 
sensitive to MMP to unmask the formulation in the cancer target site, has been proven 
effective in vivo in 4T1 breast cancer mouse model, with a clear advantage compared to the 
non-cleavable nanomedicine [135]. Similarly, PEG-based micelles bearing Paclitaxel exploited 
the MMP sensitive peptide to promote the extracellular release of the PEG layer on the surface 
and bestow superior anticancer properties [136]. MMP-cleavable linker has been used to 
conjugate albumin on the surface of silica nanoparticles, to mask their recognition by the 
mononuclear phagocyte system. At the same time, the albumin coating also masks an arginine-
rich cell penetrating peptide, which usually correlates to high cytotoxicity. The obtained 
enzyme-sensitive supramolecular system showed higher anticancer activity than the controls in 
the treatment of liver cancer HepG2 xenografts [137].  
MMP-sensitive peptidic linkers have been used also for the simple conjugation of drugs to the 
polymeric backbone, maintaining the in vivo anticancer efficacy of the free drug [138]. 
Interestingly, Peng and Kopecek developed a HPMA copolymer conjugate containing two 
enzymatically cleavable peptides: Doxorubicin has been conjugated using the conventional Gly-
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Phe-Leu-Gly Cathepsin B-sensitive linker to promote lysosomal release of the drug, while the 
MMP sensitive polypeptide was used to conjugate the HPMA copolymer to iRGD (a cyclic 
peptide targeting integrins) [139]. This conjugate should accumulate in the tumor thanks to the 
EPR effect, thus enhancing the chances of the iRGD to bind to the integrins expressed on the 
tumor endothelium and on several types of tumor cells. Finally, after MMP-mediated cleavage, 
the free iRGD promotes internalization into the target cells. Indeed, the uptake and in vitro 
activity of the conjugate were superior to the one of the free drug and of the mixture of HMPA-
Doxorubicin conjugate co-tested with free iRGD. 
In parallel, Ruan and co-workers developed gelatin-based nanoparticles presenting PEGylated 
gold nanoparticles adsorbed onto their surface. The gelatin is hydrolyzed by the MMP in the 
tumor ECM, triggering the release of the small gold nanoparticles loaded with Doxorubicin, 
which led to a slightly enhanced anticancer activity [140].  
Table III: Enzyme cleavable polymer-conjugates  
ENZYME FOR 
CLEAVAGE 
LINKER ENZYME-SENSITIVE POLYMER DRUG INDICATION REF 
Cathepsin B 
Gly-Phe-Leu-Gly HPMA copolymer 
Doxorubicin (PK1) 
Solid tumors 
[5] 
Doxorubicin (PK2) [88] 
Gly-Phe-Leu-Gly Branched HPMA Doxorubicin [97] 
Gly-Phe-Leu-Gly PEG Doxorubicin [93] 
Gly-Ile-Val-Arg-Ala-Lys Silica nanoparticles Doxorubicin [98] 
Gly-Phe-Leu-Gly 
PEGylated 
dendrimers 
Doxorubicin [95] 
Val-Cit PEG-based micelles Doxorubicin [99] 
Val-Cit PEG Camptothecin [100] 
Val-Cit PEG Paclitaxel [105] 
Gly-Phe-Leu-Gly PEG Gemcitabine [101] 
Gly-Phe-Leu-Gly HPMA copolymer Gemcitabine [103] 
Gly-Phe-Leu-Gly HPMA copolymer 
Gemcitabine 
Paclitaxel 
[102] 
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Gly-Phe-Leu-Gly 
PAMAM dendrimers 
encapsulated in 
liposomes 
Paclitaxel [104] 
Gly-Phe-Leu-Gly 
PEG- Janus 
dendrimers 
Paclitaxel [106] 
Gly-Phe-Leu-Gly 
Dendrimers 
(NTN1956) 
Doxorubicin [94] 
Peptidic bond in the 
polymeric backbone 
PGA 
Paclitaxel  
(PolyGlumex ®) 
Solid tumors 
[107]  
Paclitaxel [108] 
Oligonucleotides 
[111, 
112] 
Camptothecin [110] 
Paclitaxel, 
Doxorubicin 
[109] 
 Gly-Phe-Leu-Gly HPMA copolymer 
Paclitaxel 
Solid tumors 
[116] 
Gemcitabine 
[117]
, 
Doxorubicin 
[118] 
Gemcitabine 
Paclitaxel 
[119, 
120] 
Cathepsin K 
Gly-Gly-Pro-Nle HPMA copolymer 
Prostaglandin E1 
Bone cancer/ 
metastases 
[124] 
TNP-470  
Alendronate 
[123] 
His-Pro-Gly-Gly-Pro-Gln PEG Doxorubicin 
[126] 
Gly-Gly-Pro-Nle Pullulan 
Paclitaxel, 
Alendronate 
[125] 
Legumain 
 
Ala-Ala-Asn-Leu PEG Doxorubicin 
Solid tumor 
[131]  
Ala-Ala-Asn-Leu HA Doxorubicin [132] 
Matrix 
Metallo -
Proteinases 
Gly-Trp-Ile-Pro-Val-Ser-
Leu-Arg-Ser 
PEG-lipoparticles 
Oligonucleotides  
[134, 
135] Gly-Pro-Leu-Gly-Ile-Ala-
Gly-Gln  
PEG 
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Gelatin 
PEG-gold 
nanoparticles 
Doxorubicin [140] 
Gly-Pro-Leu-Gly-Ile-Ala-
Gly-Gln  
PEG-micelles Paclitaxel [136] 
Pro-Val-Gly-Leu-Ile-Gly 
PEG- Janus 
dendrimers 
Paclitaxel [138] 
Pro-Val-Gly-Leu-Ile-Gly Silica nanoparticles Doxorubicin [137] 
Pro-Leu-Gly-Lys-Ala-Gly HPMA copolymer Doxorubicin [139] 
 
5. ENZYME-SENSITIVE LIPOSOMES 
Liposomes are versatile non-toxic, biocompatible and biodegradable vesicle structures, whose 
lipid composition and consequent amphiphilic nature allow the encapsulation of bioactive 
molecules with distinct physicochemical properties ]141[. Different strategies have been 
devised to increase the half-life circulation of these vesicles and achieve the delivery of 
payloads to the targeted site, in order to improve their bioavailability while minimizing side-
effects. Accordingly, PEG-grafted lipids reduce liposome recognition by cells from the 
mononuclear phagocytic system, being thus extensively used to improve their stability and 
blood circulation time ]143 ,142[. These PEGylated liposomes extravasate from the altered 
vasculature at pathological sites by the EPR effect, where subsequently release loaded payloads 
through diffusion across lipid bilayer ]144[. Liposomes were the first drug nanodelivery systems 
successfully translated into the market and Doxil® was the first PEGylated liposome approved 
for the tƌeatŵeŶt of Kaposi’s saƌĐoŵa aŶd breast and ovarian cancers [145, 146]. However, 
PEGylated liposomes have limited drug release and interactions with the target cells, which 
have fostered the development of chemical tools to cleave the PEG chains once the carrier 
reaches the targeted tissue or cells [147, 148]. In addition, besides successfully modifying the 
biodistribution and pharmacokinetics of free drugs, additional strategies have been developed 
to improve the active targeting of liposomes to altered cells in order to impair off-target side 
effects. Different ligands (e.g. monoclonal antibodies and fragments, peptides, carbohydrates, 
glycoproteins) have been conjugated at the surface of liposomes to bind to specific receptors 
expressed on the target cells, enhancing the cell surface binding and/or receptor-mediated 
internalization of these vesicles [149-151]. The entrapped drugs can then diffuse through the 
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phospholipid bilayer, in a similar manner to the passive targeting of liposomes via the EPR 
effect. However, the PEG-based polymeric coating may impair the interaction of these ligands 
grafted onto the liposome bilayer with the target receptor. Therefore, additional strategies 
have been devised to remove this polymer coating as soon as the liposome reaches the target 
site, and to further trigger the release of entrapped bioactive molecules following alterations in 
the structure of liposomes in response to endogenous (e.g. overexpression of enzymes, 
reduced pH, temperature, reducing agents) or exogenous (e.g. heat, light, magnetic field) 
stimuli [152-154]. Later strategies aim to combine long-circulating liposomes, receptor 
mediated-targeting ability and stimuli-responsive systems in a single multifunctional liposomal 
formulation. These allow increased intracellular drug levels following enhanced receptor-
mediated endocytosis, but also promote the release of drug from liposomes in response to 
specific stimuli. A particularly promising approach is based on the development of liposomes 
that are sensitive to extracellular and intracellular enzymes that are increased predominantly at 
target pathological sites, such as cancer, or tissues affected by inflammation or infection. The 
structure of these enzyme-responsive liposomes can be altered by multiple enzyme-inducible 
mechanisms, including the removal of a protective polymer layer at liposomal surface, 
activation of an entrapped prodrug, destabilization of the phospholipid bilayer, and/or cleavage 
of a lipopeptide or lipopolymer dispersed within the vesicle bilayer following enzyme digestion 
(Fig. 2). These enzyme-responsive liposomes have been reviewed recently by Fouladi et al. 
[155]. Here, we will limit the discussion to those formulations relevant for PELT (Table IV). 
5.1. PLA2-sensitive liposomes 
Mock et al. engineered a liposome responsive to PLA2, an enzyme with proven anticancer 
activity (refer to section 2.2) and overexpressed at distinct pathological situations, namely 
cancer and other inflammatory pathologies, thus constituting promising targets for active drug 
delivery [156]. Different liposomal formulations have been developed using phospholipids with 
shorter fatty acid acyl chain at the anionic polar head groups, in order to attain lipid 
preferential degradation by PLA2 and consequently improve payload release [156, 157]. The 
selected PLA2-targeted liposome candidates showed a superior antitumor activity in vitro, and 
were able to decrease tumor growth at a 2.5-fold greater extent than the PEGylated 
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conventional formulation tested in a prostate cancer mouse model. Therefore, it can be 
anticipated that a two-step therapy may additionally increase the efficacy of this engineered 
formulation upon administration of a polymer-PLA2 conjugate, such as the dextrin-PLA2 
synthesized by Ferguson and Satchi-Fainaro [17]. In addition, as bacteria secrete PLA2 as well, 
and the EPR effect has also been described at sites of bacterial infection[158], these polymer-
PLA2 conjugates may comprise a promising strategy to increase the release of antibiotics at the 
infection site once delivered by the PLA2-responsive liposomes developed by Zhu et al. [157]. 
The hydrolytic activity of PLA2 was additionally improved by the presence of PEG, 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine (DSPE), distearoylphosphatidylglycerol (DSPG) 
and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) in those liposomes [159].  
Different PLA2-sensitive liposomal prodrugs have been prepared by the conjugation of lipophilic 
drugs to the acyl chain at sn-2 position in phospholipids [160-162] (Table IV). These liposomes 
showed an increased encapsulation efficacy and subsequent improved release of lipophilic 
drugs, such as retinoic acid and chlorambucil upon exposure to PLA2 specifically at the tumor 
site. Therefore, these lipid-based prodrugs are promising components of a two-stage 
nanocarrier system.  
5.2. MMP-responsive liposomes 
Following the rationale explained in section 4.3, different liposomal formulations have been 
developed using MMP-sensitive peptides, such as the MMP2-cleavable peptide Gly-Pro-Leu-
Gly-Ile-Ala-Gly-Gln bind to PEG and lipids [163, 164] (Table IV). These PEG-coated MMP-
responsive liposomes displayed a prolonged blood circulation time, and the cleavage of the 
MMP-sensitive peptides at the target site unmasked the liposomal cell surface and therefore 
improved their cellular internalization, especially if this vesicle was additionally decorated with 
a targeting moiety specific for target cells. Galactose-coated liposomes presenting a PEG layer 
attached to a phospholipid anchor via the above-mentioned MMP2-cleavable peptide linker led 
to increased uptake in HepG2 cells [163].  
5.3. Cathepsin B-responsive liposomes 
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Romberg et al. developed a liposome coated by the enzymatic-cleavable poly(amino acid)–lipid 
conjugate poly(hydroxyethyl l-glutamine)–N-succinyl-dioctadecylamine (PHEG–DODASuc) [165], 
an alternative to PEG used to transiently sterically stabilize the liposomes and increase their 
blood circulation time in rats [166]. Model proteases, such as Papain and Pronase E, but also 
the Papain-like enzyme Cathepsin B successfully degraded this PHEG polymer into 1-2 amino 
acids in vitro [167] (Table IV). The authors took advantage of this polymer coating to stabilize 
the DOPE-based liposomes to further improve the interaction with targeted cells and enhanced 
the release of the liposomal contents due to induced liposomal membrane destabilizing phase 
changes, following cleavage of PHEG-coating [165] (Fig. 2). In fact, the fusogenic lipid DOPE by 
itself does not lead to the formation of bilayer structures, resulting in lamellar and inverted 
hexagonal phases under pH above or under 9, respectively [168]. These PHEG-liposomes 
showed a calcein release rate 30% higher than the one obtained for PEG-liposomes. A clear 
increase in payload release following PHEG-coating cleavage by Pronase E was shown, and 
subsequent liposome destabilization, membrane fusion and consequent aggregation were 
observed (Fig. 2).  
As cathepsin B is primordially a lysosomal enzyme, it is a particularly interesting tool to promote 
nanocarrier endosomal escape and subsequent drug release into the cytoplasm of targeted 
cells. Zhang et al. developed pH- and enzyme-responsive liposomes containing non-bilayer 
DOPE and the stabilizer cholesterol hemisuccinate (CHEMS) [168]. Under physiological pH, 
these pH-sensitive liposomes retain their structure. However, at pH 5.5, it occurs the transition 
from lamellar to hexagonal phase, resulting in lipid destabilization and release of encapsulated 
drugs. Therefore, these pH-sensitive liposomes constitute promising candidates for the 
intracellular delivery of drugs, as their entry into the lysosomal and endosomal compartments 
foster the rapid and extensive release of entrapped payloads at targeted cellular site. DSPE-PEG 
was used to increase the blood circulation time of the DOPE-based liposomes, being anchored 
to liposomal surface by a cathepsin B-cleavable peptide (Gly-Phe-Leu-Gly) to prevent the 
previously observed reduction of pH-sensitivity of liposomes following their PEGylation [169, 
170].  Nevertheless, an increase in drug release rate from those pH- and enzyme-responsive 
liposomes was not observed in the presence of cathepsin B.  
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Figure 2. Schematic representation of the enzyme-mediated destabilization mechanisms 
responsible for an enhanced drug release from liposomes accumulated at tumor 
microenvironment via active targeting or EPR effect: 1) cleavage of phospholipids by enzymes 
increased at the extracellular matrix (e.g. Matrix metalloproteinases (MMP), legumain, 
Phospholipase A2 (PLA2), elastase) or intracellular level (e.g. cathepsins) leads to an impaired 
phospholipid bilayer and therefore enhances the release of encapsulated hydrophilic 
drugs/pro-drugs; 2) removal of enzyme-peptide conjugated PEG layer exposes the targeting 
moiety at the liposomal surface, enhancing the receptor-mediated endocytosis and subsequent 
drug release at intracellular level; and 3) cleavage of lipopeptides (e.g poly(hydroxyethyl l-
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glutamine) (PHEG)–coating) or lipopolymers dispersed within the lipid bilayer composed by 
fusogenic lipids triggers liposome fusion, further transition into the hexagonal phase, and 
consequent release of payloads. 
5.4. Other enzymes-responsive liposomes 
Elastase and prostate-specific antigen (PSA) are additional enzymes increased at inflamed 
tissues, such as tumors. Polypeptides sensitive to these enzymes, such as N-acetyl-Ala-Ala [171] 
and His-Ser-Ser-Lys-Tyr-Gln [172], respectively, have been used in the development of 
liposomal formulations to enhance payload delivery at those targeted sites. In addition, the 
conjugation of the fusogenic DOTAP to the above-mentioned elastase-sensitive linker led to a 
positively charged liposome and, consequently, to an increased fusion of this biphospholipidic 
vesicle with the lysosomal membrane, resulting in an enhanced intracellular delivery of 
liposomes and entrapped molecules. Similarly, the polyarginine peptide was conjugated to PSA-
sensitive peptide, as well as to a polyanionic peptidic domain [173]. The latter polypeptide 
establishes electrostatic interactions with the polycationic arginine, which only becomes 
activated upon the hydrolysis of the PSA-sensitive peptide as a consequence of the high 
concentrations of this enzyme at tumor tissues. The active targeting of those PSA-sensitive 
liposomes was further achieved in vivo in a prostate cancer mouse model through the use of 
folate ligands, in addition to the polyarginine peptides, resulting in a prominent reduction of 
tumor growth [172].  
 
Table IV: Enzyme-cleavable liposomes 
ENZYME FOR 
CLEAVAGE 
ENZYME SENSITIVE FUNCTION DRUG INDICATION REF 
Phospholipase A2 
(PLA2) 
1,2- distearoyl-sn-glycero-3-
phosphatidylethanolamine 
1,2-distearoyl-sn-glycero-3-
phosphatidyl- glycerol 
Doxorubicin Cancer, 
Inflammation 
[156] 
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1,2-dipalmitoyl-sn-glycero-3-
phosphocholine 
Selective retinoic acid 
ƌeĐeptoƌ βϮ ;RARβϮͿ 
agonist  
Cancer [159] 
C16 and C18 ether chains with 
phosphatidylcholine or 
phosphatidylglycerol 
headgroups 
Chlorambucil 
 
Cancer [160] 
Prostaglandine Cancer [162] 
Retinoic acid Cancer [161] 
Matrix 
Metalloproteinases 
Gly-Pro-Leu-Gly-Ile-Ala-Gly-Gln 
Cytarabine Cancer [163] 
Antinucleosome 
monoclonal antibody 
(mAb 2C5) 
Cancer [164] 
Elastase 
N-methoxy-succinyl-Ala-Ala-
Pro-Val-DOPE) 
 Cancer [171] 
Prostate-specific 
antigen (PSA) 
prostate-specific 
membrane antigen 
(PSMA) 
His-Ser-Ser-Lys-Tyr-Gln siPLK-1 Cancer [172] 
  [173] 
Pronase E poly(amino acid)–lipid 
conjugate poly(hydroxyethyl l- 
glutamine)-N-succinyl-
dioctadecylamine (PHEG–
DODASuc) 
Fluorescent calcein  [165] 
Cathepsin B Gly-Phe-Leu-Gly Doxorubicin Cancer [168] 
 
FUTURE PERSPECTIVE 
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PDEPT and PELT have never reached an advanced investigation stage and remain confined to a 
few models, partly due to the practical inconvenience of a two-step therapy. However, 
following recent advances in multiple disciplines, including cancer molecular biology, genomics, 
proteomics, tumor immunology and chemistry, novel disease markers and related mechanisms 
have been revealed, suggesting that combinatorial approaches are among the most promising 
strategies to control multifactorial pathologies, such as cancer.  On the other hand, the need for 
conjugation of drugs to polymers has highly limited the biomedical application of PDEPT. In fact, 
in the past, this technology was mainly applied to drugs that contain functional groups for 
covalent conjugation to polymers. Accordingly, paclitaxel, gemcitabine, docetaxel, irinotecan, 
camptothecin and doxorubicin have been the most used drugs for polymer conjugation [174, 
175]. In addition, the use of synthetic routes demands for an extensive physicochemical 
characterization of polymer-drug conjugates, in order to control end material properties and 
therefore, obtain reliable and reproducible stability, drug release and subsequent PDEPT/ PELT 
pharmacokinetics. Even though, significant progress on linker chemistry and materials science 
have been reported since the first generation of polymer-drug conjugates by Ulbrich and 
Kopěek [176], thus opening new opportunities for the successful application of PDEPT. More 
than 25 polymer conjugate-based products have indeed successfully been approved for human 
use [177]. This demonstrates that different options are already available to overcome those 
major drawbacks related to the conjugation of bioactive moieties to polymer backbone. One 
particularly interesting solution is the difluoroalkyl-sulfinate ketone-protected reagent 
developed by Shabat, Satchi-Fainaro and co-workers, which allows for the direct 
functionalization of C−H ďoŶd iŶ heteƌoaƌǇl dƌugs [178]. This is one example among other 
synthetic approaches (reviewed in [179]) already reported that will most likely expand the 
possible uses of PDEPT.  
This polymer-drug conjugation technology offers as well the opportunity for a selective 
triggered drug release in the target cells, in contrast to the continuous release of drugs 
entrapped within nanodelivery systems. The latter can limit the amount of drug available at 
target site following the indiscriminate release of the drugs while being delivered through 
circulation. This, in fact, has been underlying the limited clinical translation of nanomedicines 
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despite the tremendous research and investment in this field, as reviewed by Duncan and 
Gaspar [180].  
Even though, nanomedicines have dramatically changed the efficacy and systemic toxicity of 
several drugs for distinct medical applications. Liposome-based strategies are the first 
nanodelivery systems already successfully translated into the clinical use, and many are in 
different stages of clinical evaluation. In addition to being biocompatible, biodegradable and 
non-immunogenic, liposomes have well-established metabolism, pharmacokinetic and 
biodistribution profiles via different routes of administration. Doxil® was the first nanomedicine 
approved for clinical use by the FDA in 1995 [181] and constitutes an example of enhanced 
delivery of a drug, doxorubicin in this particular case, to tumor cells following extravasation-
depeŶdeŶt ;͞passive͟Ϳ targeting of PEGylated liposomes. Very recently, the FDA approved a 
liposome encapsulating a combination of daunorubicin and cytarabine (VYXEOS®, Jazz 
Pharmaceuticals, Inc.) for the treatment of acute myeloid leukaemia [12]. This is the first 
nanomedicine entrapping two drugs approved for biomedical applications, opening new 
avenues for the clinical development and regulatory approval of advanced combinatorial 
approaches using a single carrier.  
As a result, increasing developments of multifunctional nanomedicines responsive to multiple 
enzymes and/or stimuli may combine the advantages of PDEPT/PELT and nanodelivery tools in 
a single carrier. The next generation of enzyme-responsive systems developed under a new 
concept combining nanotechnology-based strategies with advanced conjugation chemistry 
may, thus, additionally overcome some of the disadvantages of a two-step therapeutic 
approach, while offering a specific molecular conjugation to increase active targeting and 
intracellular delivery of payloads. However, despite the development of multiple enzyme-
responsive delivery systems, none has been translated into clinical trials. In fact, important 
challenges still need to be overcome to optimize spatio-temporal release of the active 
compounds, to achieve a maximum therapeutic index, ensuring high drug concentration at the 
targeted tissue and reduced effects on the viability of healthy cells. In addition, clear benefit on 
therapeutic effect and improved safety must be obtained using these two-step systems 
particularly following the development of complex multifunctional enzyme-responsive 
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nanodelivery systems. The rational design should consider not only the high cost, but also the 
challenging translation into clinical use against cancer. Moreover, the treatment of other 
diseases, which pathologies could facilitate an EPR effect, may benefit from these new tools 
bridging nanotechnology and enzyme-polymer conjugate technologies. Indeed, recent evidence 
demonstrates the presence of an EPR effect in bacterial infection and supports the potential 
application of PELT for the targeted delivery of antibiotics to sites of bacterial infection [158]. 
Several liposomal antibiotic formulations are already in development or clinical use [182, 183] 
and may be useful models to combine with a suitable polymer-enzyme conjugate in future 
studies. 
Overall, besides the anticipated long process to bring these systems into clinical practice, 
significant progress in several complementary areas may change significantly the landscape of 
these enzyme-responsive systems, allowing for their full potential against multiple pathological 
situations.  
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